Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Average Recommendation of "Strong Buy" by Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) has been given a consensus recommendation of "Strong Buy" by the seven ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and five have assigned a strong buy recommendation to the company.

A number of equities research analysts recently weighed in on the company. Zacks Research upgraded Zealand Pharma A/S from a "strong sell" rating to a "hold" rating in a research report on Monday, September 15th. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. Wells Fargo & Company upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. Finally, BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st.

Zealand Pharma A/S Trading Up 0.4%

Shares of ZLDPF stock opened at $79.20 on Thursday. The firm has a market capitalization of $5.62 billion, a P/E ratio of 5.56 and a beta of 0.74. Zealand Pharma A/S has a twelve month low of $49.98 and a twelve month high of $126.00. The company has a quick ratio of 15.08, a current ratio of 15.09 and a debt-to-equity ratio of 0.02. The stock's fifty day simple moving average is $65.82 and its 200 day simple moving average is $64.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). The firm had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $9.18 billion. Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%. As a group, sell-side analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.